May Contain (+/-): Titanium Dioxide (CI 77891), Iron Oxides (CI 77491, CI 77492, CI 77499), Bismuth Oxychloride (CI 77163), Manganese Violet (CI 77742), Red 6 (CI 15850), Red 7 Lake (CI 15850), Red 21(CI 45380), Red 27 (CI 45410), Red 28 Lake (CI 45410), Red 30 Lake (CI 73360), Red 33 Lake (CI 17200), Orange 5 (CI 45370), Yellow 5 Lake (CI 19140), Yellow 6 Lake (CI 15985), Blue 1 Lake (CI 42090)
Retatrutide is an investigational triple agonist that simultaneously targets GLP-1, GIP, and glucagon receptors currently in Phase 3 clinical trials and projected for FDA review in late 2026 with potential approval in 2027 or 2028
R., Tian, L., Deng, F., Swanson, M., & Mu, L
GMR Peptides assumes no liability for any misuse of this product outside of a research context
Practical Hydration Tips Keep a refillable bottle handy, sip regularly, and drink a glass of water first thing in the morning
Ambetter provides three main tiers of coverage: Bronze, Silver, and Gold